Drugs / Autologous Adipose-Derived Mesenchymal Stromal Cells
Autologous Adipose-Derived Mesenchymal Stromal Cells
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06280092 | Dec 2024 → Mar 2026 overdue | epilepsy | Sanjeet S. Grewal | Recruiting | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03608579 | Nov 2018 → Oct 2026 expected | osteoarthritis, hip | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03461458 | Oct 2018 → Feb 2021 | intervertebral disk degenerative disorder | Mayo Clinic | Terminated | No outcome recorded |
| Phase 1 | NCT02805855 | Oct 2016 → Sep 2023 | osteoarthritis, knee | Jacob L. Sellon, M.D. | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT04785027 | Mar → Jun 2021 | psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT03392311 | Jul → Oct 2019 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT03265613 | Sep 2017 → Aug 2019 | psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT02290041 | Feb 2017 → Jul 2019 | — | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03268603 | Oct 2017 → Jan 2024 overdue | amyotrophic lateral sclerosis | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT04275024 | Apr → Jun 2020 | poisoning, psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT04212728 | Dec 2019 → Dec 2023 | osteoarthritis, knee | Yantai Yuhuangding Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05329662 Comparator | May 2023 → Jun 2025 | sexual disorder | Vinmec Research Institute of Stem Cell and Gene Technology | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Adipose Derived Mesenchymal Stromal Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03608579 ↗ |
| Known as | AD-MSCs | “This study used data from an interrupted phase I/II clinical trial to evaluate safety and immune recovery after INRs were given four infusions, at baseline and at weeks 4, 8,...” PMID 33264515 ↗ Dec 20202“AD-MSCs have been widely used as autologous and allogeneic stem cell sources to treat numerous disease recently, and they have been proven to be safe.” NCT05329662 ↗ “AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 2 million cells/kg” NCT04275024 ↗ |
| Known as | adipose-derived multipotent mesenchymal stem cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03392311 ↗ |
| Known as | Allogenic Adipose-derived Mesenchymal Stem Cells | “Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery” NCT06280092 ↗ |
| Known as | AMSCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04212728 ↗ |
| Known as | autologous adipose-derived mesenchymal stem cells | “autologous adipose-derived mesenchymal stem cells (AMSCs)” NCT04212728 ↗ |
| Known as | mesenchymal stem cells | “Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells (1 million MSCs/Kg, weeks 0-4-8-20).” NCT02290041 ↗ |
| Known as | mesenchymal stromal cells | “with human allogeneic mesenchymal stromal cells from adipose tissue (Ad-MSCs).” PMID 33264515 ↗ Dec 2020 |
| Known as | MSCs | “The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's.” NCT03268603 ↗1“Allogenic Adipose-derived Mesenchymal Stem Cells(AMSCs) for Epilepsy During Deep Brain Stimulation(DBS) Surgery” NCT06280092 ↗ |
| Modality | Cell therapy | “Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells” NCT02805855 ↗ |
| Route | Intravenous | “Intravenous infusion of 4 doses of adipose tissue derived allogeneic adult mesenchymal stem cells” NCT02290041 ↗ |